Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 50/100

Failure Rate

9.8%

21 terminated/withdrawn out of 215 trials

Success Rate

77.4%

-9.1% vs industry average

Late-Stage Pipeline

17%

36 trials in Phase 3/4

Results Transparency

4%

3 of 72 completed trials have results

Key Signals

10 recruiting3 with results12 terminated9 withdrawn

Enrollment Performance

Analytics

N/A
77(52.4%)
Phase 2
23(15.6%)
Phase 4
21(14.3%)
Phase 3
15(10.2%)
Phase 1
6(4.1%)
Early Phase 1
5(3.4%)
147Total
N/A(77)
Phase 2(23)
Phase 4(21)
Phase 3(15)
+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (215)

Showing 20 of 215 trials
NCT07560462Not ApplicableNot Yet Recruiting

Budesonide Following Endoscopic Dilatation of Esophageal Strictures in Children.

Role: lead

NCT05253560Recruiting

Prodromal Parkinsonian Features in GBA1 Mutation Carriers

Role: lead

NCT04388969Recruiting

World Data on Ambroxol for Patients With GD and GBA Related PD

Role: lead

NCT06500715Not ApplicableNot Yet Recruiting

Acupuncture as add-on to G-CSF for Febrile Neutropenia-related Hospitalization in Doxorubicin-treated Patients With Sarcoma

Role: lead

NCT05331209Not ApplicableNot Yet Recruiting

Acupuncture With/Without Self-acupressure for Post-oophorectomy Hot Flashes in BRCA Carriers

Role: lead

NCT04940780Not ApplicableRecruiting

Integrative Oncology for Patient Symptoms

Role: lead

NCT07537400Phase 2Not Yet Recruiting

Patients Between the Ages of 12 Months to 21 Years With Newly-Diagnosed High-Risk Neuroblastoma Will Receive Children's Oncology Group (COG) Type Recommended Therapy With the Addition of Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) to Induction Cycles 1-5

Role: lead

NCT05211518Not ApplicableCompleted

Prevention of Inflammatory Bowel Diseases in Persons at Risk The PIONIR (Preventing IBD Onset in Individuals at Risk) Trial

Role: lead

NCT01983410Active Not Recruiting

A Registry for BRCA Mutation Carriers With Pancreatic Ductal Adenocarcinoma

Role: collaborator

NCT05568420Recruiting

A Study of the Possible Effects of Medication on Young Onset Colorectal Cancer (YOCRC)

Role: collaborator

NCT06756581Not ApplicableEnrolling By Invitation

Tolerability of Baked Dairy Protein in Eosinophilic Esophagitis Patients With Cow Milk Protein Trigger

Role: lead

NCT05180578Not ApplicableRecruiting

Tolerability of Goat Milk Protein in Eosinophilic Esophagitis Patients With Cow Milk Protein Trigger

Role: lead

NCT04803916Recruiting

Pre-stenotic Inflammation Following Endoscopic Balloon Dilatation in Crohn's Disease: A Prospective Study

Role: lead

NCT04239248Not ApplicableCompleted

"Tasty&Healthy" Dietary Approach for Crohn's Disease

Role: lead

NCT06870266Early Phase 1Not Yet Recruiting

Comparison of Pregnancy Rates in Modified Natural Frozen Embryo Transfer (FET) Cycle After Luteal Support with GnRH Agonist Versus Progesterone

Role: lead

NCT06785844Early Phase 1Not Yet Recruiting

Intra-rectal Botulinum Toxin Injection for Intractable Non-retentive Fecal Incontinence in Children - an Open Label Pilot Study

Role: lead

NCT06777706Not ApplicableCompleted

Open Label Study to Assess Safety & Efficacy of QD for Induction of Remission in Pediatric Patients with UC

Role: lead

NCT06729476Not ApplicableCompleted

The Effect of Uroshield on Sputum-specimen Bacterial Growth

Role: lead

NCT06298188Not ApplicableRecruiting

Risankizumab in Children With Crohn's Disease (RisaKids)

Role: lead

NCT05599360Phase 2Active Not Recruiting

Vyxeos for Induction of Low- or Intermediate-risk.

Role: lead